Antiviral effect of lymphokine-activated killer cells: chemotaxis and homing to sites of virus infection.
AUTOR(ES)
Natuk, R J
RESUMO
Lymphokine-activated killer (LAK) cells generated from C57BL/6 mouse spleen cells cultured with interleukin-2 are effective prophylactically against virus infection when inoculated at the site of virus injection. To predict the therapeutic efficacy of LAK cells, we determined whether LAK cells would home to sites of virus infection. In vitro, LAK cells responded chemotactically to cell-free peritoneal exudate fluids collected from virus-infected mice and to preparations of purified beta interferon. In vivo, radiolabeled LAK cells injected intravenously accumulated in the peritoneal cavities of intraperitoneally infected mice in amounts three to eight times greater than in uninfected mice. This ability to respond to chemotactic agents and migrate into sites of virus infection may make LAK cells useful as antiviral therapeutic agents.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=251148Documentos Relacionados
- Antiviral effect of lymphokine-activated killer cells: characterization of effector cells mediating prophylaxis.
- Generation of lymphokine-activated killer cells: synergy between tumor necrosis factor and interleukin 2.
- Characterization of cytotoxic cells from reovirus-infected SCID mice: activated cells express natural killer- and lymphokine-activated killer-like activity but fail to clear infection.
- Aspergillus fumigatus contamination of lymphokine-activated killer cells infused into cancer patients.
- Recognition of typhus group rickettsia-infected targets by human lymphokine-activated killer cells.